.png "Global Insight")
It was the kind of medical news investors dream about — and the market hated it anyway. On Thursday, Moderna and Merck released detailed results from a late-stage trial of their personalized cancer vaccine: it cut the risk of melanoma coming back or killing the patient by 42%. Hours later, Moderna's stock had cratered more than 25% in its worst single-day fall on record, wiping about $24 billion off the company's value. Good science, it turns out, is not the same thing as good news for shareholders.
What the trial actually showed
The vaccine, called intismeran (also known as mRNA-4157 or V940), is not an off-the-shelf shot. It is built for each individual patient: scientists sequence the mutations unique to that person's tumour and encode them into messenger RNA, training the immune system to recognise the cancer as foreign. In the trial — more than 1,100 patients with high-risk melanoma — it was given alongside Merck's blockbuster immunotherapy Keytruda, which takes the brakes off the immune response.
According to Reuters, the combination reduced the risk of cancer recurrence or death by 42% compared with Keytruda alone, and cut the risk of distant metastasis or death by 38%. The data cover the first two years after treatment, and the full results are scheduled to be presented at the European Society for Medical Oncology meeting in Madrid. Reuters notes this is the first trial to show that a vaccine built on a patient's own tumour mutations, paired with an immune-boosting drug, can keep the disease at bay — a potential template for treating other cancers.
How a personalized cancer vaccine works
The idea is elegant, and specific to this trial rather than a generic textbook concept. Every melanoma carries a unique set of mutations — genetic typos that make the tumour different from healthy tissue. Intismeran is manufactured to encode up to 34 of those patient-specific mutations. Once injected, the patient's own cells produce the mutated proteins, the immune system flags them as threats, and T-cells learn to hunt down any remaining cancer cells carrying the same markers after surgery.
Keytruda's role is the other half of the mechanism. Tumours often survive by switching off the immune cells sent to kill them; Keytruda blocks that off-switch. The trial's logic was that the vaccine would create an army of cancer-trained immune cells, and Keytruda would keep them fighting. The 42% figure suggests the logic held — at least over two years, in this group of high-risk patients. Longer follow-up will determine whether the benefit endures, and the companies are already testing the approach in other tumour types.
Why the market punished a breakthrough
If the medicine worked, why did the money run? The answer is part leak, part expectations game. As Reuters reported, the detailed results leaked on an oncology website earlier in the day, forcing the companies to release the data ahead of schedule — and the leak spoiled the carefully staged reveal investors had been waiting for. Worse, Moderna's stock had already surged more than 500% this year on anticipation of exactly this data. Analysts had told clients they wanted to see a recurrence-risk reduction of 40% or more; the trial delivered 42% — technically a beat, but only just, after months of hype.
The result was a textbook "sell the news" reaction: Moderna closed down 25.2% at $183.88, its steepest one-day percentage fall ever, while Merck slipped nearly 1%. None of that changes the medicine. But it is a useful reminder that markets price in hope and punish adequacy — even when adequacy means a 42% cut in the risk that a deadly cancer returns.
For patients, the honest reading is narrower than the headlines. This was a trial in high-risk melanoma after surgery, not a general cancer cure, and the vaccine remains experimental — it will need regulators' sign-off and longer data before it reaches clinics. Still, a personalized mRNA vaccine that meaningfully moves survival in a large, late-stage trial is the most concrete validation yet of an idea oncology has chased for decades. The stock chart will recover or it won't; the 42% is what matters. Readers interested in the bigger cancer picture may want our report on the Lancet study linking 1 in 8 cancers to infections and our explainer on AI that predicts cancer survival from a selfie.
This article is general information only and is not medical advice.